Literature DB >> 8787128

In vivo studies of acetylcholinesterase activity using a labeled substrate, N-[11C]methylpiperdin-4-yl propionate ([11C]PMP).

M R Kilbourn1, S E Snyder, P S Sherman, D E Kuhl.   

Abstract

Two esters, N-[11C]methylpiperidyl acetate ([11C]AMP) and N-[11C]methylpiperidyl propionate ([11C]PMP), were synthesized in no-carrier-added forms and evaluated as in vivo substrates for brain acetylcholinesterase (AChE). After peripheral injection in mice, each ester showed rapid penetration into the brain and a regional retention of radioactivity (striatum > cortex, hippocampus > cerebellum) reflecting known levels of AChE activity in the brain. Regional brain distributions after [11C]PMP administration showed better discrimination between regions of high, intermediate, and low AChE activities. Chromatographic analysis of blood and brain tissue extracts showed rapid and nearly complete hydrolysis of [11C]PMP within 10 min after injection. For both [11C]AMP and [11C]PMP, retention of radioactivity in all regions was reduced by pretreatment with diisopropylfluorophosphate (DFP), a specific irreversible AChE inhibitor. DFP treatment also significantly increased the proportions of unhydrolyzed ester in both blood and brain. Radioactivity localization in brain after peripheral injection was thus dependent on AChE-catalyzed hydrolysis to the hydrophilic product N-[11C]methylpiperidinol. PET imaging of [11C]AMP or [11C]PMP distributions in monkey brain showed clear accumulation of radioactivity in areas of highest AChE activity (striatum, cortex). These esters are thus in vivo substrates for brain AChE, with potential applications as in vivo imaging agents of enzyme action in the human brain. [11C]PMP, the ester with a slower rate of hydrolysis, appears to be the better candidate radiotracer for further development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787128     DOI: 10.1002/(SICI)1098-2396(199602)22:2<123::AID-SYN5>3.0.CO;2-F

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  18 in total

1.  An improved radiosynthesis of O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate: A first-in-class cholinesterase PET tracer.

Authors:  Kiel D Neumann; Charles M Thompson; Joseph E Blecha; John M Gerdes; Henry F VanBrocklin
Journal:  J Labelled Comp Radiopharm       Date:  2017-05-15       Impact factor: 1.921

2.  PET radiopharmaceuticals for probing enzymes in the brain.

Authors:  Jason P Holland; Paul Cumming; Neil Vasdev
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-04-09

3.  Cerebral cortical and subcortical cholinergic deficits in parkinsonian syndromes.

Authors:  S Gilman; R A Koeppe; B Nan; C-N Wang; X Wang; L Junck; R D Chervin; F Consens; A Bhaumik
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

4.  The cortical cholinergic system contributes to the top-down control of distraction: Evidence from patients with Parkinson's disease.

Authors:  Kamin Kim; Martijn L T M Müller; Nicolaas I Bohnen; Martin Sarter; Cindy Lustig
Journal:  Neuroimage       Date:  2017-12-19       Impact factor: 6.556

5.  Early initiation of hormone therapy in menopausal women is associated with increased hippocampal and posterior cingulate cholinergic activity.

Authors:  Yolanda R Smith; Luvina Bowen; Tiffany M Love; Alison Berent-Spillson; Kirk A Frey; Carol C Persad; Nancy K Reame; Robert A Koeppe; Jon-Kar Zubieta
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

Review 6.  Molecular Imaging of the Cholinergic System in Parkinson's Disease.

Authors:  Nicolaas I Bohnen; Prabesh Kanel; Martijn L T M Müller
Journal:  Int Rev Neurobiol       Date:  2018-09-20       Impact factor: 3.230

7.  Thalamic cholinergic innervation makes a specific bottom-up contribution to signal detection: Evidence from Parkinson's disease patients with defined cholinergic losses.

Authors:  Kamin Kim; Martijn L T M Müller; Nicolaas I Bohnen; Martin Sarter; Cindy Lustig
Journal:  Neuroimage       Date:  2017-02-05       Impact factor: 6.556

8.  Radiosynthesis and ex vivo evaluation of [(11)C-carbonyl]carbamate- and urea-based monoacylglycerol lipase inhibitors.

Authors:  Justin W Hicks; Jun Parkes; Junchao Tong; Sylvain Houle; Neil Vasdev; Alan A Wilson
Journal:  Nucl Med Biol       Date:  2014-05-10       Impact factor: 2.408

9.  In vivo visualization of donepezil binding in the brain of patients with Alzheimer's disease.

Authors:  Nobuyuki Okamura; Yoshihito Funaki; Manabu Tashiro; Motohisa Kato; Yoichi Ishikawa; Masahiro Maruyama; Hiroyasu Ishikawa; Kenichi Meguro; Ren Iwata; Kazuhiko Yanai
Journal:  Br J Clin Pharmacol       Date:  2007-12-07       Impact factor: 4.335

Review 10.  The cholinergic system and Parkinson disease.

Authors:  Nicolaas I Bohnen; Roger L Albin
Journal:  Behav Brain Res       Date:  2010-01-07       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.